Ohana Biosciences to Participate in Oppenheimer’s Private Life Sciences Company Call Series
CAMBRIDGE, Mass., June 18, 2020 – Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced that Amber Salzman, Ph.D., President and Chief Executive Officer of Ohana, will present a company overview as part of Oppenheimer’s Private Life Sciences Company Call Series on Wednesday, July 1, 2020 at 3:00 p.m. E.T. Webcast replay will not be available; registration is available through Oppenheimer.
About Ohana Biosciences
At Ohana Biosciences, we are pioneering a reproductive health revolution through our industry-first platform of sperm-based technologies. We began with a vision to reimagine global reproductive health and help all people create the healthy family they dream of – when they are ready. Today, we believe our unprecedented understanding of sperm biology coupled with our pioneering research will turn our vision into a reality. Through our platform, we are focused on fundamental components of reproductive health: fertility, pregnancy complications, inherited disease, developmental disorders, and non-hormonal contraception. By advancing research in fertility treatments, new technologies to reduce pregnancy complications, disease transmission, and developmental disorders, and enabling non-hormonal contraception, Ohana is dedicated to becoming a leader in reproductive health and offering life-changing options for people. Ohana was founded in 2016 by Flagship Pioneering and is based in Cambridge, Mass. For more information, please visit www.OhanaBio.com.
Media and investors
Vice President, Corporate Affairs